Routine new officer Form 3 with zero reported holdings. No trading signal. Monitor future Form 4 filings by this insider for any open-market purchases or grants that would indicate insider conviction.
GANX drugs
GANX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $1.13entry
- T+1 · 14d ago +1.77%α +1.47% · $1.15
- T+5 · 8d ago −3.54%α −3.62% · $1.09
- T+11 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
How similar events traded
Executive Summary
Jeanette Weidner filed a Form 3 initial statement of beneficial ownership with the SEC, reporting no securities owned, and appointed attorneys-in-fact for Section 16 filings. The filing is a routine administrative requirement for a new officer (Principal Accounting Officer and Principal Financial Officer) and contains no material financial information.
Key Facts
- Jeanette Weidner filed a Form 3 as a new reporting person (Principal Accounting Officer and Principal Financial Officer) of Gain Therapeutics, Inc.
- The Form 3 reports zero beneficial ownership of the company's securities.
- A Power of Attorney (Exhibit 24) was included, authorizing Gene Mack, Daniel Porco, and Christopher Williams to act as attorneys-in-fact for Section 16 filings.
- The filing is dated October 30, 2026, with a period of report of October 28, 2026.
Financial Impact
No financial impact; the filing reports zero securities owned and no transactions.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001104659-26-120731 |
| Document: 0001104659-26-120731-index-headers.html | 0001104659-26-120731 |
| Document: 0001104659-26-120731-index.html | 0001104659-26-120731 |
| Document: 0001104659-26-120731.txt | 0001104659-26-120731 |
Track record
15 reports on GANX
2 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +13.74% at T+60 after the May 26, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 17, 2026today Press Release Bullish 6/10 Entry $1.19 Now $1.18 −0.84% settles Nov 25
- Nov 10, 20267d ago Press Release Neutral 4/10 Entry $1.08 Now $1.18 +9.26% due Nov 17
- Oct 30, 202618d ago 3 Neutral 2/10 Viewing Entry $1.13 to $1.09 Now $1.18 +4.42% ▼ −3.54% −3.62% vs SPY
- Oct 28, 202620d ago 8-K Neutral 2/10 Entry $1.19 to $0.9604 Now $1.18 −0.84% ▼ −19.29% −14.57% vs SPY
- Oct 1, 20266w ago Press Release Neutral 4/10 Entry $1.72 to $1.62 Now $1.18 −31.40% ▼ −6.10% −7.41% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $1.72 to $1.62 Now $1.18 −31.40% ▼ −6.10% −7.41% vs SPY
- Aug 11, 202614w ago Press Release Bullish 6/10 Entry $2.06 to $2.03 Now $1.18 −42.72% ▼ −1.46% −1.05% vs SPY
- Jul 16, 202617w ago 8-K Neutral 4/10 Entry $1.66 to $1.82 Now $1.18 −28.92% ▲ +9.64% +11.31% vs SPY
- Jun 29, 202620w ago 8-K Bullish 7/10 Entry $2.03 to $1.81 Now $1.18 −41.87% ▼ −10.84% −11.44% vs SPY
- Jun 29, 202620w ago Press Release Bullish 5/10 Entry $2.03 to $1.81 Now $1.18 −41.87% ▼ −10.84% −11.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers